A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Trial ID or NCT#
Status
Purpose
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
Official Title
Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer
Eligibility Criteria
- * Diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease.
- * Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
CCTO
650-498-7061
View on ClinicalTrials.gov